A biotech profile exploring the company’s expansion into psychedelic-based CNS therapeutics and what that strategic pivot signals for its brain-health portfolio.
Key Takeaways
- Longevity has largely been a story about cells
- Investors have chased therapies that clear out senescent cells
- It’s a question that sits quietly beneath Jupiter Neurosciences ’ latest move